EXICURE, INC.

Exicure, Inc. announced it received a notification from Nasdaq on June 5, 2026, indicating non-compliance with the minimum $2.5 million stockholders' equity requirement, having reported approximately $2.1 million as of March 31, 2026. Nasdaq also determined the company does not meet alternative listing standards. Exicure attributes this partly to executive separation and legacy consulting expenses, and has implemented cost-reduction initiatives. The company has 45 days, until July 20, 2026, to submit a plan to regain compliance, with no immediate impact on its stock listing.

Exicure, Inc. announced it received a Nasdaq non-compliance notification on May 28, 2026, for the delayed filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2026. The delay was primarily due to changes in the company's financial reporting personnel and related filing procedures. Exicure subsequently filed the Form 10-Q on May 29, 2026, and believes it has regained compliance with Nasdaq Listing Rule 5250(c)(1).

Exicure, Inc. received a Nasdaq notification on May 28, 2026, for non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The delay was attributed to changes in financial reporting personnel and procedures. The company subsequently filed the Form 10-Q on May 29, 2026, and believes it has regained compliance with Nasdaq's listing requirements.

Exicure, Inc. reported a net loss of $1.83 million for the first quarter of 2026, a significant decline from a net income of $3.01 million in the prior-year period, primarily due to the absence of a large gain on lease termination. The company's cash and cash equivalents decreased to $2.60 million, leading management to express substantial doubt about its ability to continue as a going concern without additional funding. Exicure is actively exploring strategic alternatives and faces risks related to its Nasdaq listing and ongoing legal proceedings concerning a defaulted lease.

Exicure, Inc. announced a co-development agreement with Korea-based Adbiotech Co., Ltd. to explore combination therapies utilizing Burixafor (GPC-100). The collaboration will evaluate Burixafor in indications such as sickle cell disease, acute myeloid leukemia, and solid tumors. Adbiotech will conduct in vivo studies and support preclinical validation, while Exicure will provide Burixafor and manage clinical and regulatory strategy, building on Burixafor's successful Phase 2 trial in multiple myeloma.

Exicure, Inc. announced significant leadership changes, appointing Yoontae Han as a new director and to the Audit Committee, effective April 8, 2026. Concurrently, Dongho Lee was named Chair of the Audit Committee. The company also appointed Young Seung Ko as its Chief Operating Officer on April 9, 2026, leveraging his 20+ years of global executive experience in enterprise software and public company operations.